2.77
price down icon3.99%   -0.115
after-market アフターアワーズ: 2.77
loading

4 D Molecular Therapeutics Inc (FDMT) 最新ニュース

pulisher
Mar 31, 2025

4D Molecular Therapeutics stock hits 52-week low at $3.46 - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

4D Molecular Therapeutics stock hits 52-week low at $3.46 By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 30, 2025

Charles Schwab Investment Management Inc. Sells 29,708 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 30, 2025
pulisher
Mar 27, 2025

PNC Financial Services Group Inc. Raises Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 27, 2025
pulisher
Mar 24, 2025

Here Is How Powerful 4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is - Stocks Register

Mar 24, 2025
pulisher
Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Raises Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 24, 2025
pulisher
Mar 24, 2025

Weiss Ratings Reiterates Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - The AM Reporter

Mar 24, 2025
pulisher
Mar 21, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 15.1% in February - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $30.63 - Defense World

Mar 20, 2025
pulisher
Mar 16, 2025

M&T Bank Corp Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 16, 2025
pulisher
Mar 13, 2025

Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdles - Investing.com

Mar 12, 2025
pulisher
Mar 11, 2025

Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News

Mar 11, 2025
pulisher
Mar 11, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00 by Analysts at Bank of America - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy -March 10, 2025 at 09:31 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

4D Molecular Launches Pivotal Phase 3 Trial for Revolutionary Eye Treatment - StockTitan

Mar 10, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Acquires 3,675 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by New York State Common Retirement Fund - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Analysts Issue Forecasts for FDMT Q1 Earnings - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $28.00 Price Target at Chardan Capital - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.

Mar 04, 2025
pulisher
Mar 04, 2025

Deeper Dive: Understanding 4D Molecular Therapeutics Inc (FDMT) Through its Various Ratios - The Dwinnex

Mar 04, 2025
pulisher
Mar 04, 2025

4D Molecular price target lowered to $35 from $39 at RBC Capital - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

4D Molecular Therapeutics’ (FDMT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Moderna (NASDAQ:MRNA) and 4D Molecular Therapeutics (NASDAQ:FDMT) Head to Head Review - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank of Canada - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

4D Molecular price target lowered to $28 from $30 at Chardan - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics - Benzinga

Mar 03, 2025
pulisher
Mar 03, 2025

RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 03, 2025
pulisher
Mar 02, 2025

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance UK

Mar 02, 2025
pulisher
Mar 01, 2025

4D Molecular Therapeutics Reports Strong Clinical Progress and Financial Position - TipRanks

Mar 01, 2025
pulisher
Mar 01, 2025

FDMT stock touches 52-week low at $4.4 amid sharp annual decline - Investing.com Australia

Mar 01, 2025
pulisher
Feb 28, 2025

4D Molecular Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

4D Molecular Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times

Feb 28, 2025
pulisher
Feb 28, 2025

4D Molecular Therapeutics Reports Positive Clinical Data for 4D-150 in Wet AMD and DME, Outlines Strategic Pipeline and Financial Position - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Can 4DMT's $505M Cash Runway and Promising Eye Disease Data Overcome Rising Losses? - StockTitan

Feb 28, 2025
pulisher
Feb 27, 2025

Spotlight On February 2025's Promising Penny Stocks - Simply Wall St

Feb 27, 2025
pulisher
Feb 27, 2025

4D Molecular Therapeutics (FDMT) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 25, 2025

4D Molecular Therapeutics, Inc. (FDMT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire

Feb 25, 2025
pulisher
Feb 24, 2025

Arbor Wealth Advisors LLC Raises Holdings in Apple Inc. (NASDAQ:AAPL) - Armenian Reporter

Feb 24, 2025
pulisher
Feb 23, 2025

Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $32.13 - Defense World

Feb 23, 2025
pulisher
Feb 20, 2025

4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World

Feb 20, 2025
pulisher
Feb 19, 2025

4D Molecular's March Investor Showcase: What These Two Major Conference Appearances Signal - StockTitan

Feb 19, 2025
pulisher
Feb 18, 2025

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression - Seeking Alpha

Feb 18, 2025
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
大文字化:     |  ボリューム (24 時間):